Tuesday, May 24, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

by Medical Finance
in Coronavirus
Study: Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants. Image Credit: Tatiana Shepeleva/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

The rapid outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide has resulted in the coronavirus disease 2019 (COVID-19) pandemic. This pandemic has massively affected the healthcare system and economy globally. Scientists and policymakers have formulated many pharmaceutical and non-pharmaceutical strategies to contain the pandemic.


Study: Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants. Image Credit: Tatiana Shepeleva/ShutterstockStudy: Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants. Image Credit: Tatiana Shepeleva/Shutterstock


Background


Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, SARS-CoV-2 has evolved due to mutations in the viral genome. Several SARS-CoV-2 variants have been classified as variants of concern (VOC) and variants of interest (VOI) by the World Health Organization, in accordance to their virulence, transmissibility, and ability to evade the anti-SARS-CoV-2 neutralizing antibodies (nAbs) induced via vaccination or natural infection.


Scientists have characterized the newly emerged Omicron VOC (B.1.1.529) that has become the dominant variant in many countries worldwide. In vitro studies associated with the Omicron variant using Vero cells, expressing human ACE2 and human TMPRSS2 for susceptibility to nAbs were performed. It was revealed that the Omicron strain is resistant to nAbs currently authorized or approved for clinical use (AFCU nAbs). AFCU nAbs include REGN10987 (imdevimab), LY-CoV555 (bamlanivimab), REGN10933 (casirivimab), and several other approved nAbs.


Recent studies have reported the emergence of a subset of Omicron viruses that contains an additional mutation in the spike protein at the R346K position in the receptor-binding domain (RBD). Previous studies have reported the presence of R346K mutation in SARS-CoV-2 Mu VOC. Scientists reported a decreased neutralization potency of Omicron+ R346K strain for all tested AFCU nAbs.


Previous studies that performed Omicron pseudotype neutralization assays revealed that the two of the antibodies in development, bebtelovimab, and BRII-198 (romlusevimab), were effective against the Omicron variant. BRII-198 exhibited a significantly decreased neutralizing activity against Omicron + R346K pseudoviruses.


However, not much evidence is available regarding the efficacy of bebtelovimab against Omicron + R346K pseudoviruses. The Omicron subvariant constitutes 23% of sequences submitted to GISAID. Therefore, there is an urgent need to develop effective nAbs that could protect individuals from SARS-CoV-2 VOCs.


An early COVID-19 treatment showed intravenous (IV) administration of nAbs is an effective way to treat severely infected COVID-19 patients. However, later scientists reported that another mode of delivery, i.e., intranasal (IN) delivery, could be more efficient for respiratory infection.


A new study


Researchers have shown that the production of human antibodies in transgenic animals has several advantages, such as enhanced diversity and clonal selection for antibody optimization. This enables the development of highly reactive and effective antibody therapeutics.


A new study published on the bioRxiv* preprint server has focused on the identification, in vitro binding, and potent neutralizing activity of STI-9167 (plutavimab) against live viruses and pseudotype viruses.


Scientists determined the efficacy of STI-9167 against several SARS-CoV-2 variants, including the Omicron and Omicron+ R346K variant. The K18ACE2 transgenic mouse model of COVID-19 disease helped determine the effect of STI-9167 when introduced via IN or IV. The studied mice were infected either with the original SARS-CoV-2, the Delta, or the Omicron strain.


The authors identified a pool of antibodies following immunization of mice with SARS-CoV-2 RBD protein obtained from the original SARS-CoV-2 strain. The antibody binding analysis and virus neutralization assays revealed that STI-9167 is effective against the SARS-CoV-2 original strain and several VOCs, including Delta, Omicron, and the Omicron+ R346K subvariant. The authors used virus pseudotypes to determine the STI-9167 activity against the Omicron +R346K subvariant. They also reported an excellent neutralizing ability of STI-9167 against the Mu variant. 


A previous study by the same group of researchers reported that nAb STI-2020, when administered via IN, showed higher efficacy in the SARS-CoV-2 preclinical models of pathogenesis. In this study, researchers reported that STI-9167 is effective in both delivery modes, i.e., IN and IV routes. 


The findings of this study are in line with previous studies, which revealed that the amount of virus replication found in the lungs following Omicron infection was reduced compared to the original SARS-CoV-2 variant and the Delta variant. Scientists reported that IN treatment with STI-9167, at a dose level of 5 mg/kg, in K18 ACE2 transgenic mice showed that the treated mice were protected 12 hours following the treatment. They measured the effectiveness of the treatment by comparing the weight loss and viral load in the treated and the control group of mice.


Conclusion


The authors reported that the phase 1 clinical studies associated with administering liquid drops of STI-2099 in the upper airways reported it to be safe. A phase 2 study has been completed in the US, and two other Phase 2 studies, are being conducted in Mexico and the United Kingdom. Encouraged by promising results, the cGMP drug product has been prepared to analyze its efficacy and safety in human clinical trials.


*Important notice


bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Longitudinal Assessment of SARS-CoV-2 Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multi-Cytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity. Image Credit: Merlin74 / Shutterstock.com

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

by Medical Finance
May 24, 2022
0

The World Health Organization (WHO) has reported over 361 million confirmed coronavirus disease 2019 (COVID-19) cases, of which include over...

Study: Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVD-19 respiratory disease. Image Credit: CROCOTHERY/Shutterstock

Immuno-proteomic profiling suggests aberrant immune cell regulation associated with post-COVD-19 infection

by Medical Finance
May 24, 2022
0

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic that...

Study: Clinical severity of Omicron sub-lineage BA.2 compared to BA.1 in South Africa. Image Credit: peterschreiber.media/Shutterstock

Severity of SARS-CoV-2 infections with Omicron BA.2 variant relative to the BA.1 variant in South Africa

by Medical Finance
May 24, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers estimated the clinical severity of the severe acute respiratory syndrome...

Study: Effectiveness of COVID-19 Vaccination Against SARS-CoV-2 Omicron Variant in Two Outbreaks in Indoor Entertainment Settings in Australia. Image Credit: View Apart / Shutterstock.com

Study determines effectiveness of COVID-19 vaccination against Omicron variant in high-risk indoor settings

by Medical Finance
May 24, 2022
0

The Omicron variant is the current dominant circulating strain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is...

Study: Self-Reported Mask Use in SARS-CoV-2 Vaccinated and Unvaccinated Populations. Image Credit: fizkes/Shutterstock

Study finds a consistent temporal association between mask use and COVID-19 vaccination status

by Medical Finance
May 24, 2022
0

Before the coronavirus disease 2019 (COVID-19) pandemic, the effectiveness of mask-wearing in preventing the spread of pathogenic respiratory infections was debatable due to...

New research on SARS-CoV-2 Omicron and care home residents

New research on SARS-CoV-2 Omicron and care home residents

by Medical Finance
May 24, 2022
0

Soon after the emergence of the newest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant, there has been...

Next Post
Study: A Class of Shark-Derived Single-Domain Antibodies can Broadly Neutralize SARS-Related Coronaviruses and the Structural Basis of Neutralization and Omicron Escape. Image Credit: ustas7777777 / Shutterstock.com

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

Study: The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers. Image Credit: Marcos Homem / Shutterstock.com

Canadian study estimates incidence rate of reinfection in healthcare workers

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • detail of microscope lenses observing a slide with sample wells in the laboratory angellodeco e84c7a54b30247a0a1ad679809f0b548 620x480
    New study holds promise to help plants defend themselves against viruses
  • shutterstock 1684229461
    Targeting CHI3L1 inhibits SARS-CoV-2 variants, including Delta and Omicron
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply